Skip to main content
OpenTrials
Completed

NCT Number: NCT02329223

Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult participants 12 - 75 years who received the diagnosis of refractory chronic spontaneous uriticaria and who remained symptomatic despite standard-dosed non-sedating H1 antihistamine treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Spontaneous Uriticaria

Age range

12 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis Investigative Site, Toyoake, Aichi-ken, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamine at the time of randomization
  • Chronic spontaneous urticaria diagnosis for 6 months

Key Exclusion Criteria:

  • Weight less than 20 kg
  • Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria
  • Evidence of parasitic infection
  • Any other skin diseases than chronic spontaneous urticaria with chronic itching
  • Previous treatment with omalizumab
  • Contraindications to diphenhydramine
  • History of anaphylactic shock
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study
  • History of hypersensitivity to omalizumab or to drugs of similar chemical classes
  • Pregnant or nursing (lactating) women

Treatment and study plan

Omalizumab

Biological

Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Other names: Xolair

Placebo

Other

Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.

Primary outcomes

  1. Change From Baseline in the Weekly Itch Severity Score at Week 12

    Time frame: Baseline to Week 12

    The weekly itch severity score is a component of the Urticaria Activity Score 7 (UAS7) composite score. The UAS7 is a composite score of the number of wheals (hives) and the severity of the itch. The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score from baseline indicates improvement.

Secondary outcomes

  1. Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12

    Time frame: Baseline to Week 12

    The UAS7 is a composite score of the number of wheals (hives) and the severity of the itch. The UAS7 is determined by the sum of the daily urticaria activity scores over 7 days and ranges from 0 to 42. The daily urticaria activity score is the average of the morning and evening urticaria activity scores and ranges from 0 to 6. The urticaria activity score is the sum of ratings on a scale of 0 to 3 (0=none to 3=intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticaria activity scores over the 7 days prior to the first treatment. A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement.

  2. Change From Baseline in the Weekly Number of Hives Score at Week 12

    Time frame: Baseline to Week 12

    The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement.

  3. Percentage of Participants With a UAS7 Score ≤ 6 at Week 12

    Time frame: Week 12

    The UAS7 is a composite score of the number of wheals (hives) and the severity of the itch. The UAS7 is determined by the sum of the daily urticaria activity scores over 7 days and ranges from 0 to 42. The daily urticaria activity score is the average of the morning and evening urticaria activity scores and ranges from 0 to 6. The urticaria activity score is the sum of ratings on a scale of 0 to 3 (0=none to 3=intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticaria activity scores over the 7 days prior to the first treatment. A higher urticaria activity score indicates more severe symptoms.

  4. Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12

    Time frame: Baseline to Week 12

    The weekly size of the largest hive score is the sum of the daily size of the largest hive scores over 7 days and ranges from 0 to 21. The daily size of the largest hive score is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (> 2.5 cm). The daily size of the largest hive score is the average of the morning and evening scores. The Baseline weekly size of the largest hive score is calculated over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score from baseline indicates a reduction in hive size.

  5. Percentage of Weekly Itch Severity Score Minimally Important Difference (MID) Responders at Week 12

    Time frame: Week 12

    Weekly itch severity score MID response is defined as a reduction from baseline in weekly itch severity score of ≥ 5 points.

  6. Percentage of Complete Responders (UAS7 = 0) at Week 12

    Time frame: Week 12

    Complete responders are defined as participants who achieved UAS7 = 0.

  7. Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12

    Time frame: Baseline to Week 12

    The DLQI is a 10-item dermatology-specific health-related quality of life measure. Participants rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score from baseline indicates improvement.

  8. Percentage of Participants With Production of Anti-omalizumab Antibody

    Time frame: Week 24

    Serum samples were collected for anti-omalizumab antibody testing.

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Dec 31, 2014
Registry last updated
Sep 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.